KLK4 and angioedema: Lanadelumab is a human-specific monoclonal antibody targeting plasma kallikrein that acts as an inhibitor and reduces downstream bradykinin generation; several studies showed that lanadelumab potentiates the therapeutic preventive effect for angioedema development [29,30,31,32].